P 3B for Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$ 

Name o	Name of entity		
The a	2 Milk Company Limited		
ARBN			
158 33	158 331 965		
We (the entity) give ASX the following information.  Part 1 - All issues			
You must complete the relevant sections (attach sheets if there is not enough space).			
1	+Class of +securities issued or to	Options to subscribe for ordinary shares in the	
	be issued	Company (" <b>Options</b> ") (unquoted)	
		Performance rights representing an entitlement	

Number of \*securities issued or to be issued (if known) or maximum number which may be issued 15,000,000 Options

1,600,000 Performance Rights

("Performance Rights") (unquoted)

to acquire ordinary shares in the Company

<sup>+</sup> See chapter 19 for defined terms.

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

#### **Options**

Each Option is issued pursuant to the terms and conditions of the Company's Long Term Incentive Plan ("LTIP").

Upon vesting, each Option entitles the holder to subscribe for one ordinary share in the Company ("Share") at an exercise price of NZ \$0.63 (being the 90 day VWAP for Shares traded on NZX prior to 4 August 2015, being the date the Board agreed the exercise price and the other material terms of the Options). Each Option has a term of 5 years and 9 months.

The Options will vest at the rate of 20% on each anniversary of the grant date during the term subject to satisfaction of conditions, including requisite percentage share price appreciation.

#### Performance Rights

Each Performance Right is issued pursuant to the terms and conditions of the Company's LTIP.

The term of each Performance Right is 5 years and 9 months. The Performance Rights will vest at the rate of 20% on each anniversary of the grant date during the term, subject to satisfaction of conditions, including requisite percentage share price appreciation over the base price of NZ \$0.63. Upon vesting, each Performance Right will entitle the holder to one Share.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No.

The Shares that are issued upon exercise of the Options and vesting of the Performance Rights will rank equally in all respects with the existing class of quoted Shares from the date of allotment and issue of those Shares.

5 Issue price or consideration

There is no issue price for the Options and Performance Rights

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

The grant of the Options and Performance Rights is being made to certain members of the Company's senior management team as part of the on-going long term incentive arrangements that the Company has adopted to assist in the reward, retention and motivation of its employees including its senior management.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

N/A

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

N/A

6c Number of \*securities issued without security holder approval under rule 7.1

N/A

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	<sup>+</sup> Issue dates	17 August 2015	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	-,	
	Cross reference: item 33 of Appendix 3B.		_
		[	F
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	633,066,979	Fully paid ordinary shares
			1

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
15,000,000	Options issued on 17 August 2015 with an exercise price of NZ \$0.63
5,000,000	Options issued on 31 March 2015 at an exercise price of NZ \$0.63
20,740,000	Partly paid ordinary shares
1,600,000	Performance Rights

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
		L
17	Policy for deciding entitlements in relation to fractions	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A	
33	<sup>+</sup> Issue date	N/A	
You ne	ed only complete this section if you are a  Type of <sup>+</sup> securities  (tick one)	ppiying for quotation of securities	
		pplying for quotation of securities	
(a)	+Securities described in Par	t 1	
(b)	All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entiti	es that have ticked box 34(a)		
Addi	ional securities forming a nev	w class of securities	
Tick to docum	indicate you are providing the informa	tion or	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over		

<sup>+</sup> See chapter 19 for defined terms.

37		A copy of any trust deed for the additional *securities
----	--	---

### Entities that have ticked box 34(b)

Number of \*securities for which \*quotation is sought

6,260,000

<sup>+</sup>Class of <sup>+</sup>securities for which quotation is sought

Fully paid ordinary shares in the Company

Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes, from the date the partly paid ordinary shares became fully paid ordinary shares on payment of the balance that was owing on the partly paid ordinary shares

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

Partly paid ordinary shares became fully paid ordinary shares on payment of the balance that was owing on 6,000,000 partly paid shares held indirectly by Geoffrey Babidge and 260,000 partly paid shares held directly by Peter Nathan

42 Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	+Class	
639,326,979	Fully paid ordinary shares in the Company	

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 17 August 2015

(Director/Company secretary)

Print name: Geoffrey Babidge

== == == ==

<sup>+</sup> See chapter 19 for defined terms.